IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

- 18 July 2023 - 1 mins read

Aggregated presentation by day and by market

Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code)
IPSEN549300M6SGDPB4Z94P1110/07/2023FR0010259150511108.65AQEU
IPSEN549300M6SGDPB4Z94P1110/07/2023FR00102591502,536108.53CEUX
IPSEN549300M6SGDPB4Z94P1110/07/2023FR0010259150507108.55TQEX
IPSEN549300M6SGDPB4Z94P1110/07/2023FR00102591505,255108.55XPAR
IPSEN549300M6SGDPB4Z94P1111/07/2023FR0010259150878109.08AQEU
IPSEN549300M6SGDPB4Z94P1111/07/2023FR00102591501,402108.94CEUX
IPSEN549300M6SGDPB4Z94P1111/07/2023FR0010259150633108.97TQEX
IPSEN549300M6SGDPB4Z94P1111/07/2023FR00102591505,387109.00XPAR
IPSEN549300M6SGDPB4Z94P1112/07/2023FR0010259150666108.65AQEU
IPSEN549300M6SGDPB4Z94P1112/07/2023FR00102591501,451108.65CEUX
IPSEN549300M6SGDPB4Z94P1112/07/2023FR0010259150782108.68TQEX
IPSEN549300M6SGDPB4Z94P1112/07/2023FR00102591503,640108.63XPAR
IPSEN549300M6SGDPB4Z94P1113/07/2023FR0010259150145110.02CEUX
IPSEN549300M6SGDPB4Z94P1113/07/2023FR0010259150790110.02XPAR
IPSEN549300M6SGDPB4Z94P1114/07/2023FR0010259150235110.67AQEU
IPSEN549300M6SGDPB4Z94P1114/07/2023FR0010259150242110.46CEUX
IPSEN549300M6SGDPB4Z94P1114/07/2023FR001025915065110.58TQEX
IPSEN549300M6SGDPB4Z94P1114/07/2023FR00102591501,358110.48XPAR
* Two-digit rounding after the decimalTOTAL26,483108.91

Attachment

Related Press Releases

IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
14 November 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
13 November 2023 11 mins read

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
07 November 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
Ipsen updates on QM-1114 regulatory process
03 October 2023 5 mins read

Ipsen updates on QM-1114 regulatory process
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
26 September 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
04 September 2023 5 mins read

Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
21 August 2023 15 mins read

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
26 May 2023 7 mins read

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury
09 June 2022 6 mins read

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or...
Ipsen Pledges Ambitious Action on Climate Change
27 October 2021 3 mins read

Ipsen Pledges Ambitious Action on Climate Change